Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:41.934Z.
Calculation as of: 2026-10-06T16:57:41.934Z.
Quote observation: 2026-10-06T16:55:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 127c42f84a692115bc317292f5e8c44ad9cea602a51c3ca4b81ff92f7edcc32f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Nutriband Inc.
Market Cap
$79.87M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Nutriband Inc. (NTRB) | $79.87M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.04M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A |
| Pulmonx Corporation (LUNG)vs › | $78.35M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.69M | N/A |
| LENSAR Inc (LNSR)vs › | $82.41M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $81.97M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.05M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $83.62M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
